Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > @they need to spend money for phase 1

<< Previous

Bullboard Posts

Next >>

Comment by whisky11on May 05, 2022 4:28pm

201 Views

Post# 34660088

RE:RE:@they need to spend money for phase 1

randomtask wrote:
lying lhama, what's the all time low for this?

whisky11 wrote:

SAN FRANCISCO, CA -- (MAY 4, 2022) – Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE (“TSXV”) symbol: CLAS and OTC symbol: CLAZF) (the "Company" or "Claritas")

The Company expects to file the Annual Documents as soon as available on or before June 30, 2022.

annual audited financial statements for the fiscal year ending December 31, 2021, annual management discussion & analysis for the fiscal year ending December 31, 2021, and CEO & CFO certificates related to the foregoing (collectively, the “Annual Documents”) by the May 2, 2022 filing deadline. With the passing of the May 2, 2022 deadline, the Company is in default of the requirement to file the Annual Documents, which it expected as announced in its new release of April 29, 2022, and the MCTO

has been issued to address the matter.
The Company expects to file the Annual Documents on or before June 30, 2022.

announced that further to its news release of April 29, 2022 the British Columbia

Securities Commission (the “BCSC”), the Company’s principal regulator, has today issued a management cease trade order (“MCTO”) under National Policy 12-203 Management Cease Trade Orders that prevents the Company’s CEO and CFO from trading in the securities of the Company until after the Company’s Annual Documents have been filed and the BCSC revokes the MCTO.

The MCTO does not affect the ability of other shareholders to trade their securities.

As previously disclosed in the Company’s news release of April 29, 2022, the Company applied to

the BCSC for the MCTO, because it anticipated being unable to file its

Documents are filed, the Company intends to satisfy the provisions of the alternative information guidelines in accordance with National Policy 12-203 – Management Cease Trade Orders by issuing bi-monthly status reports in the form of news releases. The default has occurred due to delays in finishing the audit due to the scope and costs involved, and the Company is actively looking to address the matter through financing negotiations and working with its auditors. Please refer to the news release of April 29, 2022, which was the Company’s anticipated default notice, for background information regarding the filing default. This news release confirms that the anticipate filing default has occurred and the MCTO granted; all other information in the April 29,

Until the Annual

2022 not changed by this news release remains current.

The MCTO will prevent the Company’s CEO and CFO from trading in the securities of the Company until the default in relation to the MCTO has been addressed, allowing the Company time to address the anticipated default while not interrupting the regular activities of public

shareholders and other securityholders of the Company.